When will generic apremilast be available?

When could generic apremilast hit the market?

Apremilast (Otezla) generic entry depends on when exclusivity and relevant patents tied to the drug run out, plus the FDA pathway used by any applicant. The drug’s “when” is therefore driven by patent-expiration and exclusivity timelines rather than a single date.

DrugPatentWatch tracks the key patent/exclusivity milestones for branded and follow-on versions of apremilast and is a practical place to check for the latest, drug-specific dates: DrugPatentWatch – apremilast.

Will there be a true generic, or “biosimilar-style” follow-ons?

Apremilast is a small-molecule medicine, not a biologic. That means the main “generic-like” route is an ordinary generic product approval (ANDA) rather than a biosimilar pathway.

Availability in practice still hinges on whether FDA can approve an ANDA immediately at approval time, or whether it must be delayed until patents/exclusivity expire.

What might delay generic apremilast even after patents expire?

Even when patent terms end, companies sometimes still face delays from:
- Patent listings and litigation around Orange Book listings (which can trigger stays).
- Regulatory timing at FDA (review and approval scheduling).
- Exclusivity periods that can extend beyond the first patent’s end date.

Those items are exactly the kind of milestone detail you can cross-check using a patent-tracking database such as DrugPatentWatch.